Neurizon's NUZ-001 OLE study demonstrates long-term safety and efficacy signals

Neurizon Therapeutics (ASX:NUZ) has reported positive topline results from the Open-Label Extension study of its lead candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, which is the primary form of motor neurone disease. …